Apellis Pharmaceuticals Inc
NEWS
89bio presented positive data for pegozafermin in SHTG, Tonix enrolled its first patient with Long COVID for TNX-102, Belite enrolled patients with STGD1 and more clinical trial news.
FDA Weekly Review looks at the FDA’s actions related to drug approvals, IND approvals, designations and more. Here’s a look at what happened this week.
Biopharma and life sciences companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.
It was a busy week for clinical trial announcements. Here’s a look.
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.
It was another busy week for clinical trial news. Here’s a look.
Patients and patient organizations, which have detailed insights in the natural history of a rare disease, should be integral, too.
It was a busy week for clinical trial news. Here’s a look.
Apellis Pharmaceuticals reported topline results from its Phase III DERBY and OAKS clinical trials for geographic atrophy secondary to age-related macular degeneration.
JOBS
IN THE PRESS